Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

被引：0
|
作者：
Jeeyun Lee
Joon Oh Park
Won Seog Kim
Se Hoon Park
Keon Woo Park
Moon Seok Choi
Joon Hyoek Lee
Kwang Cheol Koh
Seung Woon Paik
Byung Chul Yoo
Jaewon Joh
Kihyun Kim
Chul Won Jung
Young Suk Park
Young-Hyuck Im
Won Ki Kang
Mark H. Lee
Keunchil Park
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center
[2] Sungkyunkwan University School of Medicine,Division of Gastroenterology, Department of Medicine, Samsung Medical Center
[3] Sungkyunkwan University School of Medicine,Department of Surgery, Samsung Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2004年 / 54卷
关键词：
Doxorubicin; Cisplatin; Hepatocellular carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：385 / 390
页数：5
相关论文
共 50 条
  • [31] A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus
    Kulke, MH
    Wu, BY
    Clark, JW
    Enzinger, PC
    Lynch, TJ
    Vincitore, M
    Michelini, A
    Fuchs, CS
    CANCER INVESTIGATION, 2006, 24 (03) : 229 - 234
  • [32] Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma
    Conzen, SD
    Kaufman, PA
    Arvizu, C
    LeMarbre, P
    Maurer, LH
    Mott, LA
    Mills, LE
    CANCER, 1996, 78 (09) : 1906 - 1911
  • [33] Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial
    Lynn G. Feun
    Christopher O'Brien
    Enrique Molina
    Miguel Rodriguez
    Lenox Jeffers
    Eugene R. Schiff
    Angela Marini
    Niramol Savaraj
    Bach Ardalan
    Journal of Cancer Research and Clinical Oncology, 2003, 129 : 17 - 20
  • [34] Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial
    Feun, LG
    O'Brien, C
    Molina, E
    Rodriguez, M
    Jeffers, L
    Schiff, ER
    Marini, A
    Savaraj, N
    Ardalan, B
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (01) : 17 - 20
  • [35] Amsacrine and cisplatin in poor prognosis patients with metastatic transitional cell carcinoma of the urothelium: A phase-II study
    Popov, I
    Jelic, S
    Radosavljevic, D
    Nikolic-Tomasevic, Z
    EUROPEAN UROLOGY, 2001, 40 (03) : 324 - 329
  • [36] Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma
    Lin, AY
    Brophy, N
    Fisher, GA
    So, S
    Biggs, C
    Yock, TI
    Levitt, L
    CANCER, 2005, 103 (01) : 119 - 125
  • [37] A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma
    Falkson, CI
    Falkson, G
    ONCOLOGY, 1999, 57 (03) : 232 - 235
  • [38] Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
    Wu, Jennifer
    Henderson, Charles
    Feun, Lynn
    Van Veldhuizen, Peter
    Gold, Philip
    Zheng, Hui
    Ryan, Theresa
    Blaszkowsky, Lawrence S.
    Chen, HaoBin
    Costa, Max
    Rosenzweig, Barry
    Nierodzik, MaryLynn
    Hochster, Howard
    Muggia, Franco
    Abbadessa, Giovanni
    Lewis, Jonathan
    Zhu, Andrew X.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (05) : 670 - 676
  • [39] A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma
    Cohn, Allen L.
    Myers, J. William
    Mamus, Steven
    Deur, Charles
    Nicol, Steven
    Hood, Karen
    Khan, Muhammad M.
    Ilegbodu, Des
    Asmar, Lina
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (04) : 381 - 386
  • [40] A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma
    Allen L. Cohn
    J. William Myers
    Steven Mamus
    Charles Deur
    Steven Nicol
    Karen Hood
    Muhammad M. Khan
    Des Ilegbodu
    Lina Asmar
    Investigational New Drugs, 2008, 26 : 381 - 386
12345